Michael R. Hayden - 03 Jun 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Reporting relationship: Director
Issuer ticker: XENE
Reported as of: 03 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2021, 21:07:48 UTC
Prior SEC filing: 20 May 2021
Next SEC filing: 22 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Cassandra Robinson, Attorney-in-fact

Key filing fact

Michael R. Hayden filed Form 4 for Xenon Pharmaceuticals Inc. (XENE) on 03 Jun 2021.

Key facts

This page summarizes Michael R. Hayden's Form 4 filing for Xenon Pharmaceuticals Inc. (XENE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2021, 21:07.

Change

Previous filing in this sequence was filed on 20 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 03 Jun 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 10,000
Exercise price: $18.56
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.